Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension
Launched by SAO JOSE DO RIO PRETO MEDICAL SCHOOL · Jul 13, 2016
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
Introduction
Resistant hypertension (RH) is characterized when the blood pressure (BP) remains above the recommended goal after taking three antihypertensive drugs with synergistic actions, at their maximum recommended tolerated doses for at least six months; one preferably should be a diuretic. True RH should be differentiated from pseudo resistance, which occurs due to non-adherence to treatment, inadequate BP measurements, inadequate doses of medications, inappropriate therapeutic regimens, or the presence of the so-called white-coat effect.
The exact prevalence of RH is unknown. In co...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of Resistant Hypertension Must to able swallow antihypertensive drug classes at maximum tolerated doses.
- • .
- Exclusion Criteria:
- • Secondary Hypertension Chronic renal failure Coronary artery disease Atrial fibrillation Atrioventricular block Refuse or fail to follow regimen
About Sao Jose Do Rio Preto Medical School
The São José do Rio Preto Medical School is a renowned academic institution dedicated to advancing medical education, research, and clinical practice. With a strong emphasis on innovation and excellence, the school actively engages in clinical trials that contribute to the development of new therapies and treatment methodologies. Its collaborative approach involves a multidisciplinary team of healthcare professionals and researchers committed to improving patient outcomes and enhancing the quality of healthcare. By fostering a rigorous research environment, the São José do Rio Preto Medical School plays a pivotal role in shaping the future of medicine through evidence-based practices and cutting-edge clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
São José Do Rio Preto, São Paulo, Brazil
Patients applied
Trial Officials
Juan C Yugar-Toledo, MD, PhD
Study Chair
Sao Jose do Rio Preto Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials